The pharmaceutical company Sun Pharmaceuticals Industries said on Friday that it has started a Phase II clinical trial to detect the effect of the plant-derived drug AQCH for possible treatment of Covid-19 patients.
Sun Pharma said in a statement that the company got approval from the Drug Controller General in April this year to test the drug prepared with the medicinal properties obtained from the plant. The company said, “The clinical trials will be done among 210 patients at 12 centers in the country. The treatment period for patients will be 10 days. Clinical trial results are expected by October 2020.
Sun Pharma said that AQCH’s safety study on humans has been completed and this drug has been found safe for Phase II testing. According to the company, AQCH is being developed for dengue and has been found to have antiviral effects during studies on organisms in controlled environments. That is why it is being tested as an alternative to the treatment of Covid-19.